Skip to main content
    C

    Corbus Pharmaceuticals Holding (CRBP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.01
    -0.36 (-10.81%)

    Market Cap: $69.86M

    Last updated: Nov 17, 2026 at 4:37 PM ET

    Corbus Pharmaceuticals Holding (CRBP) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Corbus Pharmaceuticals Holding (CRBP) has a market cap of $69.86M and an enterprise value of $42.79M. It kept -3162.62% of revenue as net income over the last 12 months. Its share count is up 69.31% from a year earlier.

    Total Valuation

    Enterprise value is 38.75% below the market cap, as cash exceeds debt.

    Market Cap$69.86M
    Enterprise Value$42.79M
    Latest price (Nov 17, 2026)$3.01

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 7.37% in the quarter ended Sep 30, 2026 and grew 31.70% a year over 2 years.

    Shares Outstanding20.84M
    Shares Change (YoY)+69.31%
    Shares Change (QoQ)+7.37%
    Share Count Growth (2Y CAGR)+31.70%

    Valuation Ratios

    Sales and book value multiples are 12.4x and 0.7x. Its year-end P/S ranged from 9.7x to 949.5x from 2016 to 2025.

    P/S Ratio12.4x
    P/B Ratio0.7x

    Valuation history and multiples

    Price Statistics

    The stock is down 72.81% over 52 weeks and trades 43.84% below its 50-day average.

    Beta (1Y)1.83
    52-Week Change-72.81%
    1-Month Change-32.51%
    3-Month Change-69.87%
    6-Month Change-67.10%
    5-Year Change-85.95%
    10-Year Change-97.49%
    Total Return (1Y)-72.81%
    Total Return (3Y CAGR)-13.24%
    Total Return (5Y CAGR)-35.82%
    Return vs SPY (1Y)-86.50%
    Max Drawdown (1Y)-76.46%
    Max Drawdown (3Y)-95.35%
    Sharpe Ratio (1Y)-1.68
    Correlation with SPY (1Y)0.30
    50-Day Average$5.36
    200-Day Average$8.31
    52-Week Range$2.81 to $12.88
    RSI (14 Days)30.3
    Average Volume (20 Days)1.15M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.40x current liabilities, and total debt is 0.04x shareholder equity.

    Current Ratio3.40x
    Quick Ratio3.40x
    Debt / Equity0.04x

    Returns and Efficiency

    Return on invested capital is -106.71% over the last 12 months, against a 5-year average of -41.35%.

    Return on Equity (ROE)-188.58%
    Return on Assets (ROA)-130.05%
    Return on Invested Capital (ROIC)-106.71%
    Return on Capital Employed (ROCE)-135.08%
    ROIC (5Y Average)-41.35%
    Asset Turnover0.04x

    Scores

    CRBP has an Altman Z-Score of -8.76, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-8.76
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $5.05M over the last 12 months is down 42.77% from the 12 months before.

    Revenue$5.05M
    Revenue Growth (YoY)-42.77%
    Gross Profit$5.05M
    Operating Income-$121.28M
    Pretax Income-$160.00M
    Net Income-$159.84M
    EBITDA-$120.03M
    EBIT-$118.78M
    Reported EPS (TTM)-$6.10

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 68.97% of the $122.90M in total assets.

    Cash and Equivalents$30.25M
    Total Debt$3.18M
    Net Cash$27.07M
    Net Cash Per Share$1.30
    Working Capital$83.98M
    Shareholder Equity$84.76M
    Book Value Per Share$4.07
    Total Assets$122.90M
    Total Liabilities$38.14M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $34.00K of capital spending, operating cash flow left -$92.39M of free cash flow.

    Operating Cash Flow-$92.36M
    Capital Expenditures$34.00K
    Free Cash Flow-$92.39M
    FCF Per Share-$4.78
    Depreciation and Amortization$1.65M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2399.76%.

    Gross Margin100.00%
    Operating Margin-2399.76%
    Pretax Margin-3165.75%
    Net Margin-3162.62%
    EBITDA Margin-2375.05%
    EBIT Margin-2350.24%
    FCF Margin-1828.08%

    Dividends and Yields

    CRBP does not pay a dividend.

    Buyback Yield-162.95%
    Shareholder Yield-162.95%

    Stock Splits

    The last split was a 1-for-30 reverse split on Feb 14, 2023.

    Last Split DateFeb 14, 2023
    Split TypeReverse split
    Split Ratio1:30

    Peer Position

    Against 9 similar companies, CRBP has the 5th highest P/S.

    P/S Ratio12.4x vs 12.3x median
    ROIC-106.71% vs -144.80% median
    Revenue Growth (Trailing 4 Quarters, YoY)-42.77% vs +17.59% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CRBP

    What is CRBP's market cap?

    Corbus Pharmaceuticals Holding has a market cap of $69.86M. Its enterprise value, which adds debt and subtracts cash, is $42.79M.

    How many shares of CRBP are outstanding?

    Corbus Pharmaceuticals Holding has 20.84M shares outstanding. The count is up 69.31% from a year earlier.

    Does CRBP pay a dividend?

    No. Corbus Pharmaceuticals Holding does not pay a dividend.

    How much debt does CRBP have?

    Corbus Pharmaceuticals Holding has $3.18M of total debt and $30.25M of cash and equivalents, a net cash position of $27.07M.